Synthetic Naphthoquinone Derivatives as Anticancer Agents in Ovarian Cancer: Cytotoxicity Assay and Investigation of Possible Biological Mechanisms Action.

In this study, eight naphthoquinone derivatives were synthesized in yields ranging from 52 to 96% using easy, fast, and low-cost methodologies. All naphthoquinone derivatives were screened for their in vitro anti-proliferative activities against OVCA A2780 cancer cell lines. Amongst all analysed compounds, derivatives 3-5 presented the most prominent cytotoxic potential. Naphthoquinones 3 and 4, bearing sulfur-containing groups, were identified as having high potential for ROS production, in particular the superoxide anion. Furthermore, 3 and 4 compounds caused a decrease in the cell population in G0/G1 and induced more than 90% of the cell population to apoptosis. Compound 5 did not act in any of these processes. Finally, compounds 3-5 were tested for their inhibitory ability against PI3K and MAPK. Compounds 3 and 4 do not inhibit the PI3K enzyme. On the other hand, the naphthoquinone-polyphenol 5 was only able to inhibit the percentage of cells expressing pERK.

Opening the door to the development of novel Abl kinase inhibitors.

The discovery of the importance of kinase activity and its relationship to the emergence and proliferation of cancer cells, due to changes in normal physiology, opened a remarkable pathway for the treatment of chronic myelogenous leukemia through intense search of drug candidates. Six Abl kinase inhibitors have received the US FDA approval as chronic myelogenous leukemia treatment, and continuous efforts in obtaining new, more effective and selective molecules are being carried out. Herein we discuss the mechanisms of Abl inhibition, structural features and ligand/protein interactions that are important for the design of new Abl kinase inhibitors. This review provides a broad overview of binding mode predictions, through molecular docking, which can be an approach to discover novel Abl kinase inhibitors.

Estrogen receptor alpha (ERS1) SNPs c454-397T>C (PvuII) and c454-351A>G (XbaI) are risk biomarkers for breast cancer development.

There are several risk factors related to Breast Cancer (BC) risks and response to chemotherapy with SERMs. Recently some single nucleotide polymorphisms (SNPs) on ESR1 gene have been associated to this disease. However, data are still inconclusive. The present study aimed to investigate the association of SNPs c454-397T>C (also called PvuII) and c454-351A>G (so called XbaI) to incidence of sporadic BC; ERα expression in BC; tamoxifen hormonetherapy (HT-TMX) responsiveness. To do so, a cohort of BC patients was analyzed through retrospective data collection, immunohistochemistry to ERα protein, and genotyping for PvuII and XbaI SNPs by PCR-RFLP, confirmed by sequencing. Significant difference in PvuII alleles frequencies were found BC patients when compared to control samples. Patients with P allele have a 5.14-fold increased BC risk. We found higher P and X alleles frequencies in ERα positive BC and the pp and xx genotypes were observed exclusively in patients with HT-TMX-responsive BC. Taken together, data indicates that P allele as a novel sporadic BC biomarker whereas p and x alleles enhanced chemotherapy responsiveness.

Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system.

Breast cancer (BC) hormonal receptors status is assessed by immunohistochemistry (IHC), a specific, sensitive, and accessible method that guide breast cancer treatment. In this study, we evaluated progesterone receptor (PR) expression in 53 BC cases using 3 anti-PgR antibodies (AB): monoclonal (SP42 and PgR636) and polyclonal ab62621. Primary BC cases (with signed informed consent) were used to generate tissue microarray platforms, where PR expression was accessed by IHC and evaluated by the Allred score. Categorical and quantitative data are shown in percentage and mean, respectively. Concordance (CON) and correlation among ABs were analyzed by Kappa factor (Κ), Spearman's correlation coefficient (ρ) or intraclass correlation coefficient. Staining patterns of each AB were compared by paired T-Test. We noted poor CON and Κ between ab62621 vs SP42 (CON=64.1%; Κ=0.247), and ab62621 vs PgR636 (CON=62.3%; Κ=0.204), but higher CON between SP42 vs PgR636 (CON 90.6%; Κ=0.738). Data were corroborated by Mc Nemar statistical test (p=0.019, p=0.014 and p>0.05, respectively). Regarding staining intensity (SI) among PgR+ samples, we found higher proportion of weak staining and lower SI for ab62621 (48.3%; mean IS=1.6), when compared to SP42 (20.0%, mean IS=2.1, T-test p<0.01) and PgR636 (2.3, 21.9%, T-test p<0.01). Within the entire sample, similar results were observed following ρ: SP42 vs PgR636 (ρ=0.8103); ab62621 vs SP42 (ρ=0.3524); ab62621 vs PgR636 (ρ=0.4075). As for proportion of stained cells and proportion score (PS), among PgR+ samples, the mean values for ab62621 (75.4%; 4.8) were significantly higher than those of SP42 (56.3%, 4.3; T-test p<0.01) and RPG636 (60.1%; 4.2; T-test p<0.01). Similar data were found after analyzing PS for the entire sample: SP42 vs PgR636 (ρ=0.8588); SP42 vs ab62621 (ρ=0.4832); RPG636 vs ab62621 (ρ=0.4050). Our data indicate that anti-PgR monoclonal ABs, PgR636 and SP42, are, unlike ab62621, equally suitable to test BC PgR status by IHC due to their higher accuracy. Therefore, we suggest their clinical use during BC diagnosis; thus, enabling more precise therapeutic decisions to treat BC.

Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells / Metformina sinergicamente potencializa os efeitos antiproliferativos de cisplatina e etoposideo em linhagem de celulas de cancer humano de pulmao NCI-H460

OBJECTIVE: To test the effectiveness of combining conventional antineoplastic drugs (cisplatin and etoposide) with metformin in the treatment of non-small cell lung cancer in the NCI-H460 cell line, in order to develop new therapeutic options with high efficacy and low toxicity. METHODS: We used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and calculated the combination index for the drugs studied. RESULTS: We found that the use of metformin as monotherapy reduced the metabolic viability of the cell line studied. Combining metformin with cisplatin or etoposide produced a synergistic effect and was more effective than was the use of cisplatin or etoposide as monotherapy. CONCLUSIONS: Metformin, due to its independent effects on liver kinase B1, had antiproliferative effects on the NCI-H460 cell line. When metformin was combined with cisplatin or etoposide, the cell death rate was even higher. .

OBJETIVO: Testar a eficácia da combinação terapêutica de antineoplásicos convencionais (cisplatina e etoposídeo) com metformina em linhagem celular NCI-H460 de câncer de pulmão não pequenas células, a fim de desenvolver novas possibilidades terapêuticas com eficácia superior e reduzida toxicidade. MÉTODOS: Foi utilizado o ensaio de brometo de 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazólio (MTT) e calculado o índice de combinação dos fármacos estudados. RESULTADOS: Observamos que o uso de metformina em monoterapia reduziu a viabilidade celular metabólica da linhagem de células estudada. O uso de metformina em combinação com cisplatina ou etoposídeo foi sinérgico e superior à monoterapia com cisplatina ou etoposídeo. CONCLUSÕES: A metformina, devido às suas ações independentes em liver kinase B1, apresentou atividade antiproliferativa na linhagem NCI-H460 e, em combinação com cisplatina ou etoposídeo, ampliou a taxa de morte celular. .

Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells.

OBJECTIVE: To test the effectiveness of combining conventional antineoplastic drugs (cisplatin and etoposide) with metformin in the treatment of non-small cell lung cancer in the NCI-H460 cell line, in order to develop new therapeutic options with high efficacy and low toxicity. METHODS: We used the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and calculated the combination index for the drugs studied. RESULTS: We found that the use of metformin as monotherapy reduced the metabolic viability of the cell line studied. Combining metformin with cisplatin or etoposide produced a synergistic effect and was more effective than was the use of cisplatin or etoposide as monotherapy. CONCLUSIONS: Metformin, due to its independent effects on liver kinase B1, had antiproliferative effects on the NCI-H460 cell line. When metformin was combined with cisplatin or etoposide, the cell death rate was even higher.

Comparison of immunohistochemical analysis with estrogen receptor SP1 and 1D5 monoclonal antibodies in breast cancer.

In the present study, we aimed to evaluate estrogen receptor ER-alpha status in 61 breast cancer cases using Sp1 and 1D5 monoclonal antibodies. Tissue array platforms were generated containing samples of breast cancer and positive controls that were assayed by immunohistochemistry applying monoclonal primary antibodies anti-ER alpha, SP1 and 1D5. We noted a high concordance rate (96.7%) between the referred antibodies. Moreover, we calculated the Kappa factor (0.921), indicating that 1D5 and SP1 provided overlapping ERα expression results. Indeed, we observed controversial results only in 2 samples studied, which were ER-negative when stained with 1D5 and ER-positive when assessed with SP1. Total concordance of PS was obtained (Pearson and intraclass CF, 0.7351 and 0.6193, respectively). However, concordance between the antibodies seems to be more accurate in higher PS values. An excellent IS correlation between antibodies was observed throughout the population (Spearman's CF, ρ=0.9150). Following the Allred score, 17 out of 42 positive BC samples diverged, with 1D5 always pointing to weaker staining than SP1. When calculating Spearman's CF of Total Score (TS) within the population, an excellent correlation between both the antibodies (ρ=0.9238) was noted. Nonetheless, the results were less concordant among the BC-positive cases (ρ=0.7743). Indeed, 20 samples were differentially classified using the antibodies (only 3 had higher TS with 1D5). Considering the mean TS of all samples or of invasive ductal carcinoma, SP1 provided higher scores than 1D5 (p<0.05). We recommend the use of the anti-ER RMAb SP1 due to the high probability that the BC ERα status can be determined accurately as the reagent provides higher IS. Therefore, the A-score was higher than the MMAb 1D5. Ultimately, higher IS and A-score decrease the possibility of ERα status misinterpretation and, consequently, inappropriate BC treatment that would compromise the patient's quality of life and overall survival. We recommend the use of anti-ER RMAb SP1 due to the high probability that the BC ER status can be determined accurately as the reagent provides higher IS, therefore higher A-score, than the MMAb 1D5.

Prevalence of estrogen receptor alpha PvuII (c454-397T>C) and XbaI (c454A>G) polymorphisms in a population of Brazilian women

The aim of this work was to study the estrogen receptor alpha (ERS1) PvuII and XbaI gene polymorphisms prevalence in randomly selected women population from Rio de Janeiro and Espírito Santo states in Brazil by polymerase chain reaction restriction fragment lengths polymorphism (PCR_RFLP) methodology. It was shown that Rio de Janeiro women exhibited a significantly different prevalence of XbaI polymorphism comparing to Espirito Santo women. Nonetheless, similar prevalence of PvuII polymorphism was found in both women´s populations. Moreover, a strong linkage disequilibrium was observed between these SNPs reinforcing the hypothesis of differential pattern of inheritance observed on such populations.

Evaluation of PvuII and XbaI polymorphisms in the estrogen receptor alpha gene (ESR1) in relation to menstrual cycle timing and reproductive parameters in post-menopausal women.

OBJECTIVE: To evaluate the association of -397T>C and -351A>G single nucleotide polymorphisms (SNPs) - also called PvuII and XbaI, respectively - located on estrogen receptor alpha (ERS1) gene with age at menarche, menopause onset, fertility and miscarriage in a population of post-menopausal women. STUDY DESIGN: Cross-sectional study with 273 healthy, high miscegenated, post-menopausal women (mean age of 63.1±9.7 years old). Subjects were genotyped for PvuII and XbaI SNPs by PCR-RFLP and confirmed by automatic sequencing. Reproduction informations (age at menarche, age at menopause, number of pregnancies, fertility rate and miscarriages) were obtained by retrospective study using a questionnaire. RESULT(S): Age at menarche, menopause onset, number of pregnancies, total fertility rate, and parity did not seem to be influenced by any of the studied genotypes (chi-square, p>0.05). However, women carrying the xx genotype showed a 44% higher chance of miscarriage, whereas this value did not trespass 16% for any other genotype analyzed. It has been also observed a higher occurrence of miscarriage in association with combined xxpp genotype of ERS1 gene (chi-square, p<0.01). CONCLUSION(S): The present data indicate that the studied SNPs on ERS1 gene do not influence the menstrual cycle timing and parity but there is a strong relationship between the xx ERS1 SNP genotype and the incidence of miscarriage in the post-menopausal population analyzed.

O papel paradoxal do sistema imune no câncer de ovário

Introdução: O sistema imune atua nos tumores desde o surgimento destes. Observa-se que o sistema imune exerce papel paradoxal sobre os tumores: é capaz de proteger o hospedeiro contra o surgimentodestes e também de promover o crescimento tumoral. Nos cânceres de ovário clinicamente detectáveis esse padrão é mantido, pois determinadas populações celulares imunológicas exercem efeito protetor, visto quesuas presenças associadas ao tumor ou ascites correlacionam- se com maior sobrevida, maior taxa de citorredução ótima e melhor resultado clínico, ao passo que a presença de outras afeta negativamente a sobrevivência das pacientes e estão associadas à inibição das respostas imunológicas protetoras. Objetivo: O objetivo desse artigo foi realizar umarevisão da literatura acerca do tema ?o papel paradoxal do sistema imune no câncer de ovário?. Métodos: Foram selecionados livros e artigos, sendoa busca destes realizada no Portal de Periódicos CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) e na base de dados Pub Med. Conclusão: De acordo com o descrito na literatura, dentre as células do sistema imune cuja presença no tumor correlaciona-se com bom prognóstico da doença, estão as populações de linfócitos T citotóxicos, células natural killer e T natural killer e entre as células imunológicas cuja presença no tumor está relacionada com pior resultado clínico destacam-se as células T reguladoras e macrófagos (fenótipo M2). Assim, acredita- se que o perfil imunológico associado ao câncer deovário pode ter aplicação prognóstica e implicações terapêuticas que permitam melhor controle da doença e melhor qualidade de vida para as pacientes.

Background: The immune system recognizes tumors cells since their very beginning of the malignancy. It is observed that immune system has a paradoxical role on tumors: it is able to protect the host from the malignant cells but also stimulates the tumor growth. In clinically detectable ovarian cancer, this common pattern is maintained. Several immune cellular populations show a protective effect because their presence associated to the tumor or ascites are correlated to higher survival rate, cytoreduction rate, and better clinical outcome. Nevertheless, the presence of other immune cells negatively affects the survival from the patients being associated to inhibited immune response. Objective: The purpose of this article was to review the topic ?the paradoxical role of the immunesystem in ovarian cancer?. Methods: Were selected books and articles thatwas search in the CAPES?s Portal (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) and in the database Pub Med. Conclusion: According to what has been described in the literature, among immunesystem cells whose presence in the tumor correlates with good prognosis, are the populations of cytotoxic T cells, natural killer and natural killer T cells and between immune cells whose presence in the tumor is associated with worse clinical outcome are includeregulatory T cells and macrophages (M2 phenotype). Them, it is believed that immunological profile associated to ovarian cancer may be used in disease prognosis and, also, be used for therapeutic reasons thatleads to better control of such disease and improved quality of life for patients.

O papel dos polimorfismos de nucleotídeos único (SNPs) PvuII e XbaI e das pequenas repetições em tandem (STRs)(TA)n e (GT)n do receptor de estrogênio Alfa (ESR1) na suscetibilidade do câncer de mama (BRCA) da mama (BRCA) / The role of single nucleotide polymorphisms (SNPs) PvuII and XbaI and short tandem repeats (STRs) (TA)n and (GT)n of estrogen alpha receptor (ESR1) in breast cancer (BRCA) susceptibility

O estrogênio é um hormônio esteroide sexual que possui efeito sobre o sistema reprodutor feminino e masculino. Esses efeitos são mediados principalmente pelas isoformas Alfa e Beta (ER Alfa e Beta), componente da superfamília de receptores nucleares que controlam a transcrição gênica. De fato, a resposta do gene ao estrogênio depende de muitos fatores, incluindo a avaliação dos subtipos de ER, os correguladores, o tempo de exposição ao estrogênio e a quantidade desse hormônio. Os processamentos (do inglês splicing) alternativos geram diversas variantes de RNAm de ESR1. As isoformas de RNAm com distintas regiões 5 não traduzidas resultam na expressão da proteína ESR1 de diferentes tamanhos. Sabe-se que o gene ESR1 possui muitos sítios de polimorfismos que podem ser responsáveis por diferentes variantes alélicas da proteína, podendo alterar a função e a atividade dessa proteína e, então, resultar nas diferenças do efeito do estrogênio sobre o desenvolvimento de doenças. Existem vários fatores de risco relacionados ao BRCA, porém os polimorfismos do gene ESR1 contribuem de maneira expressiva para carcinogênese mamária. Os SNPs Pvu II e Xba I e os STRs (GT)n e (TA)n despertam curiosidade por se localizarem em regiões não traduzidas do gene ESR1 e poderem estar relacionados a doenças de grande impacto, como o BRCA. Nota-se certa interferência desses polimorfismos nessa neoplasia, porém os resultados são divergentes. Contudo, é importante ampliar o conhecimento da genética do ESR1, pois existem evidências que suas propriedades interferem no desenvolvimento do BRCA.